相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours
P. A. Zucali et al.
BRITISH JOURNAL OF CANCER (2013)
Cyclic isoDGR Peptidomimetics as Low-Nanomolar v3 Integrin Ligands
Michele Mingozzi et al.
CHEMISTRY-A EUROPEAN JOURNAL (2013)
Biselectivity of isoDGR Peptides for Fibronectin Binding Integrin Subtypes α5β1 and αvβ6: Conformational Control through Flanking Amino Acids
Alexander Bochen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Comparative pharmacokinetics of a tumour-targeting therapy candidate rh-IFNα2a-NGR with rh-IFNα2a administered intravenously in mice and rats
Xue-Xi Wang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Nanoparticle Delivered Vascular Disrupting Agents (VDAs): Use of TNF-Alpha Conjugated Gold Nanoparticles for Multimodal Cancer Therapy
Mithun M. Shenoi et al.
MOLECULAR PHARMACEUTICS (2013)
IsoDGR-Tagged Albumin: A New v3 Selective Carrier for Nanodrug Delivery to Tumors
Flavio Curnis et al.
SMALL (2013)
Molecular Dynamics Reveal that isoDGR-Containing Cyclopeptides Are True αvβ3 Antagonists Unable To Promote Integrin Allostery and Activation
Michela Ghitti et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Antibody-cytokine fusion proteins
Roland E. Kontermann
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
D. Lorusso et al.
BRITISH JOURNAL OF CANCER (2012)
Immunocytokines: a novel class of potent armed antibodies
Nadine Pasche et al.
DRUG DISCOVERY TODAY (2012)
Radiolabelled RGD peptides for imaging and therapy
F. C. Gaertner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
Arianna Calcinotto et al.
JOURNAL OF IMMUNOLOGY (2012)
TumorHoPe: A Database of Tumor Homing Peptides
Pallavi Kapoor et al.
PLOS ONE (2012)
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Anna Johansson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Intratumoral TNFα improves immunotherapy
Anna Johansson et al.
ONCOIMMUNOLOGY (2012)
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
S. Mammoliti et al.
ANNALS OF ONCOLOGY (2011)
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy
Eleonora Dondossola et al.
CANCER RESEARCH (2011)
Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
Vanesa Gregorc et al.
CLINICAL CANCER RESEARCH (2011)
Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Angelo Corti et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients
Ingrid M. E. Desar et al.
EUROPEAN JOURNAL OF RADIOLOGY (2011)
Isoaspartate-dependent molecular switches for integrin-ligand recognition
Angelo Corti et al.
JOURNAL OF CELL SCIENCE (2011)
Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic Tissues
Paola Di Matteo et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2011)
Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR
Baolai Zhang et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2011)
Conformational Control of Integrin-Subtype Selectivity in isoDGR Peptide Motifs: A Biological Switch
Andreas O. Frank et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Gold Nanoparticles for Biology and Medicine
David A. Giljohann et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Carlos Mas-Moruno et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
A. Santoro et al.
BRITISH JOURNAL OF CANCER (2010)
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Hanneke W. M. van Laarhoven et al.
CLINICAL CANCER RESEARCH (2010)
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
Armando Santoro et al.
EUROPEAN JOURNAL OF CANCER (2010)
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
Vanesa Gregorc et al.
EUROPEAN JOURNAL OF CANCER (2010)
Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching
Flavio Curnis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Targeting of drugs and nanoparticles to tumors
Erkki Ruoslahti et al.
JOURNAL OF CELL BIOLOGY (2010)
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
Vanesa Gregorc et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects
Jeannette Gerspach et al.
BIOFACTORS (2009)
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience
Ralf Bieker et al.
BLOOD (2009)
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
V. Gregorc et al.
BRITISH JOURNAL OF CANCER (2009)
Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system
Raghav Goel et al.
NANOMEDICINE (2009)
The neovasculature homing motif NGR: more than meets the eye
Angelo Corti et al.
BLOOD (2008)
Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-α
Luca Crippa et al.
CANCER RESEARCH (2008)
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif
Flavio Curnis et al.
CANCER RESEARCH (2008)
Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots
Marlies Ostendorp et al.
CANCER RESEARCH (2008)
Structural basis for the interaction of isoDGR with the RGD-binding site of αvβ3 integrin
Andrea Spitaleri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ
Anna Maria Gasparri et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Preclinical safety evaluation of IFNα2a-NGR
Jieru Meng et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2008)
Vasculature targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer
Maria T. S. Bertilaccio et al.
PROSTATE (2008)
The moonlighting enzyme CD13: old and new functions to target
Paola Mina-Osorio
TRENDS IN MOLECULAR MEDICINE (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease
Johanna Lahdenranta et al.
FASEB JOURNAL (2007)
High-yield expression, purification and characterization of tumor-targeted IFN-alpha 2a
J. Meng et al.
CYTOTHERAPY (2007)
The structure and main functions of aminopeptidase N
Yepeng Luan et al.
CURRENT MEDICINAL CHEMISTRY (2007)
cNGR: A novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo
Alexandra Buehler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Spontaneous formation of L-isoaspartate and gain of function in fibronectin
Flavio Curnis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin
E Balza et al.
CLINICAL CANCER RESEARCH (2006)
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha
A Sacchi et al.
CLINICAL CANCER RESEARCH (2006)
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas
HWM van Laarhoven et al.
INVESTIGATIONAL NEW DRUGS (2006)
Targeted delivery of IFNγ to tumor vessels uncouples antitumor from counterregulatory mechanisms
F Curnis et al.
CANCER RESEARCH (2005)
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor α coupled to NGR and RGD tumor-homing peptides
N Zarovni et al.
HUMAN GENE THERAPY (2004)
Coupling tumor necrosis factor-α with αv integrin ligands improves its antineoplastic activity
F Curnis et al.
CANCER RESEARCH (2004)
Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin
A Sacchi et al.
CANCER RESEARCH (2004)
Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery
GF Paciotti et al.
DRUG DELIVERY (2004)
Current uses of isolated limb perfusion in the clinic and a model system for new strategies
AMM Eggermont et al.
LANCET ONCOLOGY (2003)
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
JA Joyce et al.
CANCER CELL (2003)
The roles of IFNγ in protection against tumor development and cancer immunoediting
H Ikeda et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Therapeutic cancer targeting peptides
OH Aina et al.
BIOPOLYMERS (2002)
Tumor rejection by disturbing tumor stroma cell interactions
S Ibe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
SV Bhagwat et al.
BLOOD (2001)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells
ZH Qin et al.
IMMUNITY (2000)
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
JHW de Wilt et al.
BRITISH JOURNAL OF CANCER (2000)
TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
AH van der Veen et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
